The authors suggest that the preliminary clinical report found that organic Ganoderma lucidum (hereinafter referred to as organic Ganoderma lucidum) preparations can reduce the blood glucose of some diabetic patients, but also enhance the efficacy of hypoglycemic agents. Because Ganoderma lucidum can also regulate blood lipids, reduce blood viscosity and plasma viscosity, can improve cardiovascular and cerebrovascular disease in patients with hemorheology disorders, so hypoglycemic at the same time, it is possible to delay the occurrence of diabetic vascular disease.
Diabetes is a disease that is second only to cancer and cardiovascular disease that seriously endangers human health. At present, the prevalence of diabetes in China is rising, the prevalence of major cities has exceeded 10%. The incidence and diet, genetic, environmental factors and immune system dysfunction are closely related. Diabetes major clinical manifestations of elevated blood sugar, drink, eat, polyuria, weight loss, fatigue, decreased resistance and so on. Blood glucose elevation criteria: fasting blood glucose ≥ 7.8mmol / L or 140mg / dl; 2 hours after the meal blood glucose ≥ 11.1mmol / L or 200mg / dl. Recently, the International Committee of Experts on Diabetes Diagnosis and Classification recommended the use of fasting blood glucose to diagnose diabetes, the criteria for distinguishing diabetes and non-diabetes from fasting blood glucose ≥ 140 mg / dl to ≥ 126 mg / dl and defining normal fasting blood glucose as <110 mg / Dl. There is growing evidence that the risk of diabetes increases as fasting blood glucose reaches 100 mg / dl.
Diabetes itself is not terrible, terrible is diabetes can lead to a variety of serious complications, such as heart, cerebrovascular disease, mainly high blood lipids, atherosclerosis caused by high blood pressure, coronary heart disease and cerebral insufficiency; glomerular blood vessels Hardening, leading to diabetic nephropathy and even renal failure; retinal arteriosclerosis causes diabetic retinopathy, blurred vision, and even blindness; multiple peripheral neuritis and toe necrosis. Diabetic patients died of cardiovascular and cerebrovascular syndrome accounted for more than 60%, 12% died of renal disease. Therefore, in addition to lowering blood sugar, the treatment of diabetes but also to prevent or treat the syndrome. Currently used for hypoglycemic drugs are more, such as a variety of insulin preparations, oral hypoglycemic glibenclamide (glibenclamide), the United States and Pita, the United States Kang, A Fu Ming and so on.
Clinical report of organic Ganoderma adjuvant therapy for diabetes mellitus
At the 2002 International Symposium on Ganoderma lucidum, a clinical study showed that organic Ganoderma lucidum capsules (0.25 grams per tablet, containing 10% of the organic extract of Ganoderma lucidum, 10% of organic Ganoderma lucidum spore powder + 10%) were significant Enhance the effect of conventional oral hypoglycemic agents on hypoglycemic effect in patients with type 2 diabetes mellitus. There were no significant differences in fasting blood glucose between the conventional oral hypoglycemic group (30 cases) and the organic Ganoderma lucidum capsule + conventional oral hypoglycemic group (100 cases). Treatment of organic Ganoderma lucidum capsule + conventional oral hypoglycemic group blood glucose was significantly lower than before treatment, and with conventional oral hypoglycemic agents after treatment were also significantly different. However, there was no significant change in serum insulin levels between the two groups (Table 7-1). Organic Ganoderma lucidum capsule in enhancing the hypoglycemic effect of hypoglycemic agents at the same time, but also significantly improve the patient's dizziness, thirst, fatigue, backache, leg soft and other symptoms.
Another report observed the efficacy of Ganoderma lucidum extract in the treatment of 71 patients with type 2 diabetes, and 71 patients with type 2 diabetes met the criteria for type 2 diabetes mellitus. Patients were enrolled in the course of more than 3 months, not used insulin, age 18 years old, ECG normal, not used sulfonylurea fasting blood glucose (FPG) of 8.9 ~ 16.7mmol / L, or with sulfonyl Pregnant fasting blood glucose 10mmol / L in patients. Patients were randomly divided into Ganoderma lucidum and placebo group, Ganoderma lucidum oral Ganoderma lucidum extract 1800mg, 3 times a day for 12 weeks. The placebo group served the same placebo. Both groups were measured for fasting and postprandial glycosylated hemoglobin, blood glucose, insulin and C-protein. As a result, Ganoderma lucidum extract significantly reduced glycosylated erythropoietin from 8.4% before administration to 7.6% at 12 weeks. The changes of fasting blood glucose (FPG) and postprandial blood glucose (PPG) were parallel to that of glycosylated hemoglobin, and the blood glucose was 13.6% mmol / L before administration, and dropped to 11.8mmol / L after 12 weeks. While the above-mentioned indicators of the placebo group did not change or increase. There were also significant differences in the levels of insulin and C-peptide between fasting and postprandial 2 hours. The patient can well tolerate the drug. The results indicate that Ganoderma lucidum extract is effective in patients with type 2 diabetes mellitus.
Ganoderma lucidum adjuvant therapy for diabetes mellitus
As early as the 20th century, 70 ~ 80 years of pharmacological studies that Ganoderma has hypoglycemic effect. To normal rats or mice Ganoderma lucidum solid water extract can make blood glucose significantly reduced, and that the effective component of hypoglycemic effect of Ganoderma lucidum contained polysaccharides. Injection of alloxan into experimental mice can induce hyperglycemia similar to that of human type 1 (insulin-dependent) diabetes by destroying islet cells, and injections or gavage of Ganoderma lucidum polysaccharide can increase the experimental high level induced by alloxan Blood glucose levels in serum and lower blood glucose levels. Further studies have also found that the role of Ganoderma lucidum polysaccharide with its inhibition of alloxan-induced increase in oxygen free radicals and lipid hyperoxidation, protection of pancreatic islet B cells, to maintain its insulin secretion function at a more normal level. Ganoderma lucidum also significantly increased liver glucosease, phosphofructose, glucose-6-phosphate dehydrogenase activity, reduce liver glycogen content. These findings suggest that hypoglycemic effects of Ganoderma lucidum may be due to its antioxidant activity in the body, protect islet B cells, increase plasma insulin levels, accelerate glucose metabolism, and promote peripheral tissue and liver glucose utilization results The
We also found that Ganoderma lucidum polysaccharides on streptozotocin-induced diabetic nephropathy in mice have a significant preventive effect, can significantly reduce the side of kidney disease in mice with glomerular lesions and urinary protein content. And it is proved that this effect is related to the anti-oxidative scavenging effect of Ganoderma lucidum polysaccharide. Further studies have shown that Ganoderma lucidum polysaccharide through the anti-oxidation, inhibition of low density lipoprotein (LDL) oxidation, inhibition of oxidized low density lipoprotein (ox-LDL), glycation end products (AGE) caused by vascular endothelial cell adhesion Molecule-1 (VCAM-1) expression, thereby inhibiting monocyte adhesion to vascular endothelial cells, and thus reduce or delay the diabetic patients in hyperglycemia and hyperlipidemia and other pathological factors under the influence of vascular disease.
Now that diabetes is an autoimmune disease, viral infection or some chemical poison can be directly or indirectly induced immune pathology, with autoimmune pancreatitis or islet cell damage, resulting in diabetes. So to correct the immune abnormalities in the treatment of diabetes occupies a certain position. Ganoderma lucidum immune regulation may also be related to the efficacy of prevention and treatment of diabetes. Recently, we found that Ganoderma lucidum polysaccharides on multiple injections of small doses of streptozotocin (MLD-STZ) caused by immunological diabetes in mice have a significant protective effect. Ganoderma lucidum polysaccharide can not only reduce the blood glucose level and the formation rate of diabetes mellitus in MLD-STZ-induced autoimmune diabetes mellitus, but also promote the expression of glucose transporter 2 (GLUT2) protein and improve the insulin secretion function of islet cells. In addition, Ganoderma lucidum to improve the immune function of patients with diabetes also help prevent diabetes prone to bacteria, viral infection.
The current treatment of diabetes in the program, in addition to insulin and a variety of oral hypoglycemic agents to reduce blood sugar, the need to actively control their syndrome. Ganoderma lucidum, although some patients have a direct hypoglycemic effect, but for the majority of patients should be combined with the original hypoglycemic agents to increase the efficacy of prevention or reduce the syndrome. In the case of normal blood sugar to maintain stability, according to the specific circumstances, as appropriate, the original dose of hypoglycemic agents to reduce the adverse reactions to drugs. Ganoderma lucidum itself has the role of liver can also reduce or prevent some oral hypoglycemic agents on liver damage.